DRW Securities’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

DRW Securities’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-43,000	Closed	-$545K	–	478
2017 Q3	$545K	Buy	+43,000	New	+$547K	0.17%	28
2016 Q2	–	Sell	-140,450	Closed	-$2.33M	–	102
2016 Q1	$2.33M	Buy	140,450 +109,450	+353%	+$1.92M	0.14%	28
2015 Q4	$672K	Buy	+31,000	New	+$603K	0.07%	40
2015 Q3	–	Sell	-43,500	Closed	-$1.51M	–	117
2015 Q2	$1.51M	Sell	43,500 -235,500	-84%	-$7.19M	0.16%	27
2015 Q1	$7.25M	Buy	279,000 +190,990	+217%	+$3.5M	1.13%	11
2014 Q4	$1.13M	Buy	+88,010	New	+$1.1M	0.13%	53
2014 Q1	–	Sell	-20,000	Closed	-$152K	–	261
2013 Q4	$152K	Buy	+20,000	New	+$108K	0.01%	196

Other funds holding HZNP

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DRW Securities's HZNP Position: Q4 2017 in Review

DRW Securities sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2017, closing a stake of 43,000 shares — an estimated $545K sold.

DRW Securities first reported a position in HZNP in Q4 2013 and held it in 7 quarters. The position peaked at $7.25M in Q1 2015. 183 funds tracked by Wall St. Rank hold HZNP as of Q4 2017.

DRW Securities reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2017 after selling out during the quarter.
DRW Securities sold 43,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2017, an estimated $545K.
DRW Securities first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2013 and held it in 7 quarters.
DRW Securities's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $7.25M in Q1 2015.
183 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2017.

Based on DRW Securities's 13F filing for Q4 2017, filed 14 Feb 2018.